Hikal Ltd (HIKAL) — shareholding pattern, promoter holding, financials and share price
About Hikal Ltd (HIKAL)
Hikal Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as HIKAL and on the BSE under scrip code 524735. Its ISIN is INE475B01022.
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune. [1]
Hikal Limited is an Indian fine chemicals and CDMO company supplying APIs, advanced intermediates, crop protection actives, animal health APIs and specialty chemicals globally, operating five manufacturing sites and an R&T centre with a focus on contract development and manufacturing services for global innovators and customers across Americas, Europe, Japan, LATAM and RoW.
Q3 FY26 marked a clear operational recovery for Hikal Limited after regulatory remediation: consolidated revenue recovered to INR494 crore and EBITDA expanded to INR83 crore, driven by resumed pharmaceutical supplies, improved capacity utilization and remediation largely completed at the inspected facility, restoring near‑term commercial momentum.
Listed peers in Pharmaceuticals: Morepen Laboratories Ltd, Panacea Biotec Ltd, Dishman Carbogen Amcis Ltd, Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd.
Valuation & Returns
10 Jul 2026At ₹244.75 a share on 10 Jul 2026, Hikal Ltd (HIKAL) was valued at a price-to-earnings ratio of 83.25x against an industry P/E of 36.41x and a price-to-book of 2.39x on a book value of ₹102.38 per share as of Mar 2025. Solomo computes return on equity of -3.87% and return on capital employed of -0.8% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 83.25x
- Industry P/E
- 36.41x
- P/B
- 2.39x
- EPS (TTM)
- ₹-3.96
- Book value / share
- ₹102.38
- ROE
- -3.87%
- ROCE
- -0.8%
- ROA
- -1.93%
- Debt / equity
- 0.61x
- Dividend yield
- 0.41%
- EBITDA margin
- 8.71%
- 52-week range
- ₹145.95 – ₹355
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Hikal Ltd (HIKAL) reported revenue of ₹1,713 crore, net profit of ₹-49 crore and earnings per share of ₹-3.96. That compares with revenue of ₹1,860 crore and net profit of ₹91 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹519 crore and net profit ₹14 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 |
| Net profit (₹ cr) | 160 | 78 | 70 | 91 | -49 |
| EPS (₹) | 13.02 | 6.36 | 5.64 | 7.36 | -3.96 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.93% | 4.29% | -1.44% | 4.21% |
| Profit growth | 9.16% | 1.49% | -17.27% | 30.46% |
| Stock price CAGR | 8% | -15% | -8% | -32% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.85% of Hikal Ltd (HIKAL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.99% and domestic institutional investors (DII) hold 7.24%. Market capitalisation was ₹3,018 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D) FUND 3.24%, TATA MUTUAL FUND - TATA SMALL CAP FUND 2.68%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.85% | - | 0.99% | 7.24% | 31.15% |
| Mar 2026 | 68.85% | - | 1.43% | 7.2% | 31.15% |
| Dec 2025 | 68.85% | - | 2.3% | 7.05% | 31.15% |
| Sep 2025 | 68.85% | - | 4.23% | 5.16% | 31.15% |
| Jun 2025 | 68.85% | - | 5.36% | 4.02% | 31.15% |
| Mar 2025 | 68.85% | - | 5.69% | 3.8% | 31.15% |
| Dec 2024 | 68.85% | - | 6.06% | 3.48% | 31.15% |
| Sep 2024 | 68.85% | - | 6.78% | 3.58% | 31.15% |